Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)

BACKGROUND: Androgen deprivation therapy (ADT) for prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonists can be improved. OBJECTIVE: To assess safety, the frequency and severity of hot flushes (HFs), bone health, and antitumor effects of high-dose estetrol (HDE4) when combined w...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur Urol Open Sci
Egile Nagusiak: Coelingh Bennink, Herjan J.T., van Moorselaar, Jeroen A., Crawford, E. David, Roos, Erik P.M., Somford, Diederik M., Roeleveld, Ton A., de Haan, Tjard D., van Melick, Harm H.E., Reisman, Yacov, Zimmerman, Yvette, van Osta, Gonnie, Krijgh, Jan, Shore, Neal D., Saad, Fred, Schally, Andrew V., Debruyne, Frans M.J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2021
Gaiak:
Prostate Cancer
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8317802/
https://ncbi.nlm.nih.gov/pubmed/34337526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.euros.2021.04.005
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak